SON NGUYEN: Open Payments
NPI 1194025866 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,538 in 46 payments from 15 companies in 2025. Trend: 2023 $1,114 · 2024 $1,017 · 2025 $1,538
Food & beverage: $1,185Education: $353
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 10 | $407 |
| PFIZER INC. | 10 | $214 |
| Novartis Pharmaceuticals Corporation | 5 | $147 |
| Madrigal Pharmaceuticals | 1 | $143 |
| SEAGEN INC. | 1 | $93 |
| Caris MPI, Inc. | 3 | $88 |
| Eisai Inc. | 4 | $88 |
| Janssen Biotech, Inc. | 2 | $74 |
| EMD Serono, Inc. | 2 | $67 |
| Daiichi Sankyo Inc. | 2 | $51 |
Products named: XTANDI, PLUVICTO, REZDIFFRA, MI CANCER SEEK, Lenvima, DATROWAY, ERLEADA, Padcev.
Industry payments across CA — which companies pay providers there.
